<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Fri, 21 Aug 2026 06:35:33 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform</title>
   <link>http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Beta Bionics Positives: 1) unique AID algorithm on the iLet insulin pump that requires significantly less patient interaction; 2) solid pipeline, led by Beta’s expected entry into the patch pump market in 2027; and 3) leading pharmacy channel mix among the major tubed pump manufacturers.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=BBNX&quot;&gt;click here&lt;/a&gt;. For more ratings news on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=BBNX&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Beta Bionics, Inc. closed at $19.48 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform</title>
   <link>http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Beta Bionics Positives: 1) unique AID algorithm on the iLet insulin pump that requires significantly less patient interaction; 2) solid pipeline, led by Beta’s expected entry into the patch pump market in 2027; and 3) leading pharmacy channel mix among the major tubed pump manufacturers.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=BBNX&quot;&gt;click here&lt;/a&gt;. For more ratings news on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=BBNX&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Beta Bionics, Inc. closed at $19.48 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Beta Bionics Positives: 1) unique AID algorithm on the iLet insulin pump that requires significantly less patient interaction; 2) solid pipeline, led by Beta’s expected entry into the patch pump market in 2027; and 3) leading pharmacy channel mix among the major tubed pump manufacturers.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=BBNX&quot;&gt;click here&lt;/a&gt;. For more ratings news on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=BBNX&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Beta Bionics, Inc. closed at $19.48 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Beta Bionics Positives: 1) unique AID algorithm on the iLet insulin pump that requires significantly less patient interaction; 2) solid pipeline, led by Beta’s expected entry into the patch pump market in 2027; and 3) leading pharmacy channel mix among the major tubed pump manufacturers.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=BBNX&quot;&gt;click here&lt;/a&gt;. For more ratings news on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=BBNX&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Beta Bionics, Inc. closed at $19.48 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Market+Perform/26958331.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Tandem Diabetes Care (TNDM) at Outperform</title>
   <link>http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Tandem Positives: 1) full pipeline led by the Mobi tubeless pump (expected year-end), which could be the first new tubeless pump to market; 2) a shifting selling model to the preferred pharmacy channel; 3) strong U.S. commercial presence; and 4) underpenetrated international market opportunity.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=TNDM&quot;&gt;click here&lt;/a&gt;. For more ratings news on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=TNDM&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Tandem Diabetes Care closed at $22.57 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Tandem Diabetes Care (TNDM) at Outperform</title>
   <link>http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Tandem Positives: 1) full pipeline led by the Mobi tubeless pump (expected year-end), which could be the first new tubeless pump to market; 2) a shifting selling model to the preferred pharmacy channel; 3) strong U.S. commercial presence; and 4) underpenetrated international market opportunity.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=TNDM&quot;&gt;click here&lt;/a&gt;. For more ratings news on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=TNDM&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Tandem Diabetes Care closed at $22.57 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Tandem Diabetes Care (TNDM) at Outperform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Tandem Positives: 1) full pipeline led by the Mobi tubeless pump (expected year-end), which could be the first new tubeless pump to market; 2) a shifting selling model to the preferred pharmacy channel; 3) strong U.S. commercial presence; and 4) underpenetrated international market opportunity.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=TNDM&quot;&gt;click here&lt;/a&gt;. For more ratings news on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=TNDM&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Tandem Diabetes Care closed at $22.57 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>William Blair Starts Tandem Diabetes Care (TNDM) at Outperform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</link>
   <description>&lt;p&gt;William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;Tandem Positives: 1) full pipeline led by the Mobi tubeless pump (expected year-end), which could be the first new tubeless pump to market; 2) a shifting selling model to the preferred pharmacy channel; 3) strong U.S. commercial presence; and 4) underpenetrated international market opportunity.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=TNDM&quot;&gt;click here&lt;/a&gt;. For more ratings news on Tandem Diabetes Care &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=TNDM&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Tandem Diabetes Care closed at $22.57 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Tandem+Diabetes+Care+%28TNDM%29+at+Outperform/26958326.html</guid>
   <pubDate>Fri, 21 Aug 2026 06:35:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TNDM</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G/A  Beta Bionics, Inc.                     Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26922681.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26922681.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26922681.html</guid>
   <pubDate>Thu, 13 Aug 2026 17:12:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G/A  Beta Bionics, Inc.                     Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26922681.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26922681.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26922681.html</guid>
   <pubDate>Thu, 13 Aug 2026 17:12:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Beta Bionics, Inc. (BBNX) PT Lowered to $30.40 at Ladenburg Thalmann</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Lowered+to+%2430.40+at+Ladenburg+Thalmann/26838876.html</link>
   <description>Ladenburg Thalmann analyst Jeffrey Cohen lowered the price target on Beta Bionics, Inc. (NASDAQ: BBNX) to $30.40  (from $32.00) while maintaining a Buy rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Lowered+to+%2430.40+at+Ladenburg+Thalmann/26838876.html</guid>
   <pubDate>Thu, 30 Jul 2026 07:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Beta Bionics, Inc. (BBNX) Misses Q2 EPS by 19c</title>
   <link>http://www.streetinsider.com/Earnings/Beta+Bionics%2C+Inc.+%28BBNX%29+Misses+Q2+EPS+by+19c/26836131.html</link>
   <description>&lt;p&gt;Beta Bionics, Inc. (NASDAQ: BBNX) reported Q2 EPS of ($0.53), $0.19 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $32 million.&lt;/p&gt;&lt;p&gt;For earnings history and earnings-related data on Beta Bionics, Inc. (BBNX) &lt;a href=&quot;http://www.streetinsider.com/ec_earnings.php?q=BBNX&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Earnings/Beta+Bionics%2C+Inc.+%28BBNX%29+Misses+Q2+EPS+by+19c/26836131.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:52:23 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Form  10-Q       Beta Bionics, Inc.        For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+30/26835491.html</link>
   <description>si-local-file:///var/storage/secattach/20260729/26835491.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+30/26835491.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:21:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  10-Q       Beta Bionics, Inc.        For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+30/26835491.html</link>
   <description>si-local-file:///var/storage/secattach/20260729/26835491.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+30/26835491.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:21:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  8-K        Beta Bionics, Inc.        For: Jul 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jul+29/26834791.html</link>
   <description>si-local-file:///var/storage/secattach/20260729/26834791.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jul+29/26834791.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  8-K        Beta Bionics, Inc.        For: Jul 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jul+29/26834791.html</link>
   <description>si-local-file:///var/storage/secattach/20260729/26834791.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jul+29/26834791.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance</title>
   <link>http://www.streetinsider.com/Press+Releases/Beta+Bionics+Announces+Second+Quarter+2026+Financial+Results+and+Updates+Full+Year+2026+Guidance/26834722.html</link>
   <description>&lt;p&gt;IRVINE, Calif., July  29, 2026  (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second Quarter 2026 Financial Highlights &amp;amp; Key Metrics&lt;/strong&gt;&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-bottom:6pt;&quot;&gt;Net sales of $32.0 million, up 38% compared to $23.2 million in the second quarter of 2025. &lt;ul type=&quot;circle&quot;&gt;&lt;li style=&quot;margin-bottom:6pt;&quot;&gt;Durable Medical Equipment (DME) channel net sales of $20.4 million, up 9% compared to $18.6 million in the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Beta+Bionics+Announces+Second+Quarter+2026+Financial+Results+and+Updates+Full+Year+2026+Guidance/26834722.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Beta+Bionics+Announces+Second+Quarter+2026+Financial+Results+and+Updates+Full+Year+2026+Guidance/26834722.html</link>
   <description>&lt;p&gt;IRVINE, Calif., July  29, 2026  (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second Quarter 2026 Financial Highlights &amp;amp; Key Metrics&lt;/strong&gt;&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-bottom:6pt;&quot;&gt;Net sales of $32.0 million, up 38% compared to $23.2 million in the second quarter of 2025. &lt;ul type=&quot;circle&quot;&gt;&lt;li style=&quot;margin-bottom:6pt;&quot;&gt;Durable Medical Equipment (DME) channel net sales of $20.4 million, up 9% compared to $18.6 million in the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Beta+Bionics+Announces+Second+Quarter+2026+Financial+Results+and+Updates+Full+Year+2026+Guidance/26834722.html</guid>
   <pubDate>Wed, 29 Jul 2026 16:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>UBS Assumes Beta Bionics, Inc. (BBNX) at Buy</title>
   <link>http://www.streetinsider.com/New+Coverage/UBS+Assumes+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Buy/26822776.html</link>
   <description>&lt;p&gt;UBS analyst Patrick Wood assumes coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Buy rating and a price target of $22.00.&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=BBNX&quot;&gt;click here&lt;/a&gt;. For more ratings news on Beta Bionics, Inc. &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=BBNX&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of Beta Bionics, Inc. closed at $15.99 yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/UBS+Assumes+Beta+Bionics%2C+Inc.+%28BBNX%29+at+Buy/26822776.html</guid>
   <pubDate>Tue, 28 Jul 2026 08:01:57 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Beta Bionics, Inc.                     Filed by: Divisadero Street Capital Management, LP</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+Divisadero+Street+Capital+Management%2C+LP/26814476.html</link>
   <description>si-local-file:///var/storage/secattach/20260724/26814476.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+Divisadero+Street+Capital+Management%2C+LP/26814476.html</guid>
   <pubDate>Fri, 24 Jul 2026 18:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Beta Bionics, Inc.                     Filed by: Divisadero Street Capital Management, LP</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+Divisadero+Street+Capital+Management%2C+LP/26814476.html</link>
   <description>si-local-file:///var/storage/secattach/20260724/26814476.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Beta+Bionics%2C+Inc.+++++++++++++++++++++Filed+by%3A+Divisadero+Street+Capital+Management%2C+LP/26814476.html</guid>
   <pubDate>Fri, 24 Jul 2026 18:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Beta Bionics, Inc. (BBNX) PT Raised to $19 at Goldman Sachs</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Raised+to+%2419+at+Goldman+Sachs/26770431.html</link>
   <description>Goldman Sachs analyst David Roman raised the price target on Beta Bionics, Inc. (NASDAQ: BBNX) to $19.00  (from $17.00) while maintaining a Buy rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Raised+to+%2419+at+Goldman+Sachs/26770431.html</guid>
   <pubDate>Wed, 15 Jul 2026 06:24:53 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Beta Bionics, Inc. (BBNX) PT Raised to $22 at Truist Securities</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Raised+to+%2422+at+Truist+Securities/26759648.html</link>
   <description>Truist Securities analyst Richard Newitter raised the price target on Beta Bionics, Inc. (NASDAQ: BBNX) to $22.00  (from $18.00) while maintaining a Buy rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Beta+Bionics%2C+Inc.+%28BBNX%29+PT+Raised+to+%2422+at+Truist+Securities/26759648.html</guid>
   <pubDate>Mon, 13 Jul 2026 07:08:08 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	  </item>
  <item>
   <title>Form  4/A        Beta Bionics, Inc.        For: Jun 26  Filed by: Feider Stephen</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+26++Filed+by%3A+Feider+Stephen/26730002.html</link>
   <description>si-local-file:///var/storage/secattach/20260702/26730002.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+26++Filed+by%3A+Feider+Stephen/26730002.html</guid>
   <pubDate>Thu, 02 Jul 2026 18:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
  <item>
   <title>Form  4/A        Beta Bionics, Inc.        For: Jun 26  Filed by: Feider Stephen</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+26++Filed+by%3A+Feider+Stephen/26730002.html</link>
   <description>si-local-file:///var/storage/secattach/20260702/26730002.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Beta+Bionics%2C+Inc.++++++++For%3A+Jun+26++Filed+by%3A+Feider+Stephen/26730002.html</guid>
   <pubDate>Thu, 02 Jul 2026 18:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BBNX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.51115677</category>
   	  </item>
 </channel>
</rss>
